Analysis of intravesical recurrence after bladder-preserving therapy for muscle-invasive bladder cancer

Japanese Journal of Clinical Oncology

Volumn 42, Issue 9, 2012, Pages 825-830

  Onozawa, Mizuki ^a   Miyanaga, Naoto ^a,b   Hinotsu, Shiro ^a,c   Miyazaki, Jun ^a   Oikawa, Takehiro ^a   Kimura, Tomokazu ^a   Takaoka, Ei Ichiro ^a   Kawai, Koji ^a   Shimazui, Toru ^a,d   Sakurai, Hideyuki ^d   Nishiyama, Hiroyuki ^a   Akaza, Hideyuki ^a,e  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b Mito Saiseikai General Hospital   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d UNIVERSITY OF TSUKUBA HOSPITAL   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

Drug therapy; Preservation; Radiation; Recurrence; Urinary bladder neoplasms

Indexed keywords

CISPLATIN; KI 67 ANTIGEN; METHOTREXATE;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER PRESERVING THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; CORRELATION ANALYSIS; DISEASE FREE INTERVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; PATIENT SELECTION; RADIATION DOSE; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCG VACCINE; CANCER VACCINES; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYSTECTOMY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRA-ARTERIAL; KI-67 ANTIGEN; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84865552004     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys105     Document Type: Article

References (27)

1. NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer Version 2.2011, 2012. http://www.nccn.org/professionals/physician_gls/ pdf/bladder.pdf.
2. European Association of Urology. Guidelines on Bladder Cancer. Muscle-invasive and Metastatic, 2010. http://www.uroweb.org/gls/pdf/07_Bladder%20Cancer_LR%20II.pdf.
3. Dalbagni G, Genega E, Hashibe M, et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001;165:1111-6.
4. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001;19:666-75.
5. Schoenberg MP, Gonzalgo ML. Management of invasive and metastatic bladder cancer. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh Urology, 9 edn. PA: Saunders, 2007;2468-78
6. Froehner M, Brausi MA, Herr HW, Muto G, Studer UE. Complications following radical cystectomy for bladder cancer in the elderly. Eur Urol 2009;56:443-54.
7. Liedberg F, Holmberg E, Holmäng S, et al. Long-term follow-up after radical cystectomy with emphasis on complications and reoperations: a Swedish population-based survey. Scand J Urol Nephrol 2012;46:14-8.
8. Marks LB, Kaufman SD, Prout GR, Jr, Heney NM, Griffin PP, Shipley WU. Invasive bladder carcinoma: preliminary report of selective bladder conservation by transurethral surgery, upfront MCV (methotrexate, cisplatin, and vinblastine) chemotherapy and pelvic irradiation plus cisplatin. Int J Radiat Oncol Biol Phys 1988;15:877-83.
9. Eapen L, Stewart D, Danjoux C, et al. Intraarterial cisplatin and concurrent radiation for locally advanced bladder cancer. J Clin Oncol 1989;7:230-5.
10. Shipley WU, Kaufman DS, Zehr E, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002;60:62-7.
11. Weiss C. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy. Int J Radiat Oncol Biol Phys 2008;70:1502-6.
12. Eapen L, Stewart D, Collins J, Peterson R. Effective bladder sparing therapy with intra-arterial cisplatin and radiotherapy for localized bladder cancer. J Urol 2004;172:1276-80.
13. Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993;11:2150-7.
14. Mori K, Nomata K, Noguchi M, Eguchi J, Hayashi N, Kanetake H. Long-term follow up of patients with invasive bladder carcinoma receiving combined cisplatin-based intra-arterial chemotherapy and radiotherapy. Int J Urol 2007;14:591-4.
15. Hashine K, Kusuhara Y, Miura N, Shirato A, Sumiyoshi Y, Kataoka M. Bladder preservation therapy conducted by intra-arterial chemotherapy and radiotherapy for muscle invasive bladder cancer. Jpn J Clin Oncol 2009;39:381-6.
16. Azuma H, Inamoto T, Ibuki N, et al. Novel bladder preservation therapy for locally invasive bladder cancer: combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation. Int J Oncol 2010;37:773-85.
17. Ganaha F, Yamada T, Ujita M, Irie T, Fukuda Y, Fukuda K. Intraarterial low-dose cisplatin via an indwelling port and concurrent radiotherapy for invasive bladder cancer. J Vasc Interv Radiol 2001;12:379-84.
18. Tsukamoto S, Ishikawa S, Tsutsumi M, Nakajima K, Sugahara S. An organ-sparing treatment using combined intra-arterial chemotherapy and radiotherapy for muscle-invading bladder carcinoma. Scand J Urol Nephrol 2002;36:339-43.
19. Shipley WU, Zietman AL, Kaufman DS, Coen JJ, Sandler HM. Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates-the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. Semin Radiat Oncol 2005;15:36-41.
20. Miyanaga N, Akaza H, Okumura T, et al. A bladder preservation regimen using intra-arterial chemotherapy and radiotherapy for invasive bladder cancer: a prospective study. Int J Urol 2000;7:41-8.
21. Miyanaga N, Akaza H, Hinotsu S, et al. Background variables for the patients with invasive bladder cancer suitable for bladder-preserving therapy. Jpn J Clin Oncol 2007;37:852-7.
22. Hinotsu S, Akaza H, Isaka S, et al. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study. Urology 2006;67:545-9.
23. Hinotsu S, Akaza H, Ohashi Y, Kotake T. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 1999;86:1818-26.
24. Gray R. Some diagnostic methods for Cox regression models through hazard smoothing. Biometrics 1990;46:93-102.
25. Zietman AL, Grocela J, Zehr E, et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 2001;58:380-5.
26. Takaoka E, Hinotsu S, Joraku A, et al. Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: a single institutional retrospective long-term follow-up study. Int J Urol 2010;17:623-8.
27. Hinotsu S, Akaza H, Naito S, et al. Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer. BJU Int 2011;108:187-95.